

ОСОБЕННОСТИ ФЕНОТИПА НКТ-КЛЕТОК В ЗАВИСИМОСТИ ОТ ИСХОДА РАСПРОСТРАНЕННОГО ГНОЙНОГО ПЕРИТОНИТА

А. А. Савченко¹,

А. Г. Борисов¹,

И. В. Кудрявцев^{2,3},

В. Д. Беленюк¹

¹ФГБНУ Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук», обособленное подразделение «НИИ медицинских проблем Севера», Красноярск, Россия;

²ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации, Санкт-Петербург, Россия.

³ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург, Россия.

DISSEMINATED PURULENT PERITONITIS OUTCOME AFFECTS NKT CELL PHENOTYPE

A. A. Savchenko^a,

A. G. Borisov^a,

I. V. Kudryavcev^{b,c},

V. D. Belenjuk^a

^a Laboratory of Cellular Molecular Physiology and Pathology, Federal Research Center 'Krasnoyarsk Science Center', Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North, Krasnoyarsk, Russia (660022, Krasnoyarsk, P. Geleznyaka street, 3G)

^b Federal State Budgetary Institution of Higher Education 'Academician I.P. Pavlov First St. Petersburg State Medical University', Russian Ministry of Health, St. Petersburg, Russia

^c Federal State Budgetary Scientific Institution 'Institute of Experimental Medicine', St. Petersburg, Russia

Резюме.

Целью исследования явилось изучение особенностей фенотипа NKT-клеток у больных распространенным гнойным перитонитом (РГП) в динамике послеоперационного периода в зависимости от исхода заболевания. Обследовано 52 пациента с острыми хирургическими заболеваниями и травмами органов брюшной полости, осложнившимися РГП, и 68 здоровых людей в качестве лиц контрольной группы. Забор крови у больных производили перед операцией (дооперационный период), а также на 7-е, 14-е и 21-е сутки послеоперационного периода. В зависимости от исхода заболевания в послеоперационном периоде, все больные РГП были разделены на две группы: больные с благоприятным исходом заболевания (n=34), пациенты с неблагоприятным исходом (n=18). Исследование фенотипа NKT-лимфоцитов крови проводили методом проточной цитометрии с использованием прямой иммунофлуоресценции цельной периферической крови с моноклональными антителами. У обследованных пациентов с РГП независимо от исхода заболевания в дооперационном периоде понижено относительное и абсолютное содержание NKT-клеток, причем в обеих группах больных процентное количество клеток восстанавливается сразу после операции. В то же время, абсолютный уровень NKT-клеток нормализуется только у больных с благоприятным исходом РГП и только к 21-м суткам после операции. К концу периода обследования у больных с благоприятным исходом РГП в периферической крови нормализуется содержание зрелых NKT-лимфоцитов и значительно снижается количество цитотоксических клеток, что, по-видимому, определяется их миграцией в зону воспаления. Только у больных с благоприятным исходом РГП пониженный уровень неклассических (экспрессирующие CD8-маркер) зрелых и цитокин-продуцирующих NKT-клеток в дооперационном периоде нормализуется до контрольных значений к концу периода послеоперационного обследования. В то же время, у пациентов с неблагоприятным исходом заболевания содержание данных субпопуляций NKT-клеток к 21-м суткам

послеоперационного лечения понижено. У больных с благоприятным исходом заболевания выявляется высокий уровень зрелых и цитотоксических CD11b⁺NKT-клеток уже в дооперационном периоде, тогда как при неблагоприятном исходе РПП повышенное содержание цитотоксических CD11b⁺NKT-клеток обнаружено только к 21-м суткам после операции. Содержание NKT-клеток с экспрессией активационных маркеров (CD28 и CD57), сниженное у больных в дооперационном периоде, при благоприятном исходе нормализуется сразу после операции, тогда как при неблагоприятном исходе ближе к концу послеоперационного обследования. Установленные особенности фенотипа NKT-клеток у больных с неблагоприятным исходом РПП характеризуют нарушения в соотношении субпопуляционного состава и механизмах функционирования данной фракции клеток, что определяет необходимость разработки иммунотерапевтических методов, направленных на стимуляцию иммунорегуляторной активности NKT-клеток.

Ключевые слова: перитонит; NKT-клетки; фенотип; исход заболевания; послеоперационный период, CD3⁻CD56⁺

Abstract

The aim of our study was to investigate the main characteristics of peripheral blood NKT cell phenotype in patients with disseminated purulent peritonitis (DPP) in dynamics of postoperative period, depending on the disease outcome. Fifty-two patients with acute surgical diseases and injuries of the abdominal organs complicated by DPP, and 68 healthy individuals in control group, were examined. Blood sampling was performed before surgery (preoperative period), as well as on the day 7, 14 and 21 of postoperative period. All patients with DPP were divided into two groups depending on disease outcome in postoperative period: patients with favorable disease outcome (n = 34); and patients with unfavorable outcome (n = 18). Study of the phenotype of blood NKT lymphocytes was performed by flow cytometry using direct immunofluorescence of whole peripheral blood samples with

monoclonal antibodies. The low relative and absolute level of NKT cells was observed in DPP patients regardless of outcome disease in preoperative period. At the same time, the absolute level of NKT cells returned to normal only in patients with favorable DPP outcome and only by day 21 after surgery. Patients with favorable DPP outcome by the end of examination period had normalized quantity of mature NKT-lymphocytes and significantly decreased level of cytotoxic cells which was apparently associated with migration of such cell subsets to site of inflammation. A reduced level of non-classical (expressing CD8 marker) mature and cytokine-producing NKT cells was detected only in patients with favorable DPP outcome in preoperative period which returned to normal by the end of postoperative period. At the same time, patients with unfavorable disease outcome had reduced quantity of NKT cells of these subsets by day 21 of postoperative treatment. Patients with favorable outcome had high level of mature and cytotoxic CD11b⁺ NKT cells already in the preoperative period, while patients with unfavorable DPP outcome had increased level of cytotoxic CD11b⁺ NKT cells only by day 21 after surgery. The proportion of NKT cells expressing activation markers (CD28 and CD57) was reduced in patients in preoperative period that returned to normal immediately after surgery with favorable outcome, while it recovered with unfavorable outcome closer to the end of postoperative examination. The defined features of NKT cell phenotype in patients with unfavorable DPP outcome characterize disturbances in subset ratio and mechanisms of functioning of this cell fraction. This determines a need to develop immunotherapeutic methods aimed at stimulating immunoregulatory activity of NKT cells.

Keywords: peritonitis; NKT cells; phenotype; disease outcome; postoperative period, CD3⁻CD56⁺

1 **Introduction**

2 Disseminated purulent peritonitis (DPP) remains one of the unsolved
3 problems of modern abdominal surgery due to high morbidity and mortality. The
4 disease is a complication of a number of surgical diseases or abdominal injuries
5 (acute appendicitis, perforated gastric and duodenal ulcer, acute gangrenous
6 cholecystitis, pancreatic necrosis, perforation of hollow organs, their damage during
7 trauma, etc.) in the vast majority of cases [22, 27, 28]. Mortality in DPP is about 20-
8 30%, reaching the highest figures in the development of multiple organ failure and
9 septic shock, the prevention and relief of which are key in the treatment of peritonitis
10 [33, 34].

11 It has been proven that the course of the infectious process in the abdominal
12 cavity, and the nature and characteristics of the development of purulent
13 postoperative complications, are determined not only by the severity of the
14 underlying disease, and the adequacy of the surgical intervention performed and the
15 completeness of the intensive care, but also by the functional state of the immune
16 system [3, 19, 24]. Yang et al. (2022) reported that patients with spontaneous
17 bacterial peritonitis had IL-13 overexpression in their ascites and a reduced
18 functional activity of CD8⁺ T cells [41]. There is evidence that an increased level of
19 macrophage mannose receptor (CD206) expression on peritoneal macrophages was
20 associated with an increased risk of an adverse outcome of peritonitis [38].
21 Previously, we found that the number of 'naïve' B lymphocytes and B2 cells non-
22 expressing and expressing CD23 in patients with an unfavorable outcome of DPP
23 was higher than in patients with a favorable outcome of this disease [2]. Violations
24 of the mechanisms of the respiratory burst of neutrophils as well as a decrease in
25 their phagocytic activity, and the level of TNF- α synthesis in patients with DPP,
26 were previously identified and presented in a number of publications [5, 21].

27 Natural killer T cells (NKT) are defined as a heterogeneous subset of T
28 lymphocytes with a CD3⁺CD16/56⁺ phenotype, i.e. they combine the phenotypic
29 characteristics of T and NK cells [11, 40]. Accordingly, the functional activity of

30 NKT cells is realized in various mechanisms of the immune response, realizing the
31 relationship between natural resistance and adaptive immunity. This lymphocyte
32 subset is involved in the mechanisms of antiviral and antiparasitic protection, and
33 also secreted different immunoregulatory cytokines in the site of inflammation [1,
34 10, 12]. In addition, NKT cells are able to stimulate and inhibit antitumor immune
35 responses [9, 39].

36 Semi-invariant $\alpha\beta$ -TCR expressed by NKT cells could recognize α -
37 glycuronylceramides (one of the main components of gram-negative bacteria cell
38 wall) that led to the formation of a complex of antimicrobial functions including
39 those mediated by the induction of CD40L and pronounced stimulation of Th1 and
40 Th2 lymphocytes [10, 16]. Therefore, NKT cells are also involved in immune-
41 inflammatory processes development. For instance, Nilsson et al. demonstrated that
42 NKT cell cytokine profile switching regulated liver sterile inflammation [31]. It was
43 shown that NKT cells made a significant contribution to mucosal immunity
44 regulation by intestinal homeostasis controlling and participating in the development
45 of inflammatory diseases of the abdominal cavity [11].

46 Thus, the aim of our investigation was to study the characteristics of NKT cell
47 phenotype in patients with DPP in the dynamics of the postoperative period in
48 depending on the outcome of the disease.

49

50 **Materials and Methods**

51 **Study participants.** Fifty-two patients with acute surgical diseases and
52 injuries of the abdominal organs complicated by DPP aged 25-65 years (the mean
53 age of the patients was 49.6 years) who were treated at the Krasnoyarsk regional
54 purulent-septic center at the Regional Clinical Hospital were examined. Exclusion
55 criteria from the study were the presence of acute destructive pancreatitis (pancreatic
56 necrosis), total mesenteric thrombosis, oncological diseases and tuberculosis. The
57 volume of surgical intervention and the number of sanations were determined by the
58 attending physician depending on the patient's condition. Blood sampling was
59 performed before the surgery (preoperative period) as well as on the 7th, 14th and

60 21st days of the postoperative period. All patients were divided into two groups
61 depending on the outcome of peritonitis in the postoperative period: group 1 –
62 patients with a favorable outcome of the disease (n=34); and group 2 – patients with
63 an unfavorable outcome (n=18). Sixty-eight healthy people were examined as a
64 control group.

65 All studies were performed with the informed consent of the patients and in
66 accordance with the Helsinki Declaration of the World Association 'Ethical
67 Principles Of Scientific Medical Research Involving Humans' as amended in 2013
68 and 'Rules Of Clinical Practice In The Russian Federation' approved by the Order of
69 the Russian Ministry of Health (19.06.2003, No. 266).

70 **Flow cytometry.** Study of the phenotype of NKT cells was performed by flow
71 cytometry using direct immunofluorescence of whole peripheral blood with
72 monoclonal antibodies (Beckman Coulter, USA). The preparation of blood samples
73 and the adjustment of the flow cytometer were carried out in accordance with the
74 recommendations presented in the article by Khaidukov et al. [7]. The distribution
75 of antibodies along the fluorescence channels was carried out in accordance with the
76 principles of panel formation for multicolor cytofluorometric studies [4].
77 Immunophenotyping of cells was performed by staining 200 µl of whole EDTA-
78 stabilized blood with the following combination of fluorochrome-conjugated
79 monoclonal antibodies: anti-CD3 Alexa Fluor 700 (clone UCHT1, isotype – Mouse
80 IgG1), anti-CD8 Allophycocyanin (clone B9.11, isotype – Mouse IgG1), anti-
81 CD11b Phycoerythrin-Texas Red-X (clone J33, isotype – Mouse IgG1), anti-CD16
82 Phycoerythrin-Cyanin 7 (clone 3G8, isotype – Mouse IgG1), anti-CD28
83 Phycoerythrin (clone CD28.2, isotype – Mouse IgG1), anti-CD45 Alexa Fluor 750
84 (clone J33, isotype – Mouse IgG1), anti-CD56 Phycoerythrin-Cyanine 5.5 (clone
85 N901, isotype – Mouse IgG1), and anti-CD57 Fluorescein Isothiocyanate (clone
86 NC1, isotype – Mouse IgM).

87 Incubation of blood samples with antibodies was carried out for 15 min at
88 room temperature and in the dark. Lysis of erythrocytes was carried out for 15 min
89 using 2 ml of VersaLyse Lysing Solution (Beckman Coulter, Inc., USA) with the

90 addition of 50 μ l of IOTest 3 Fixative Solution (Beckman Coulter, Inc., USA).
91 Stained cells were analyzed on a Navios flow cytometer (Beckman Coulter, Inc.,
92 USA) of the Krasnoyarsk Regional Center of Research Equipment of Federal
93 Research Center 'Krasnoyarsk Science Center SB RAS'. At least 50000 lymphocytes
94 were analyzed for each blood sample. The obtained data were analyzed using the
95 Kaluza software package (Beckman Coulter, Inc., USA).

96 **Statistical analysis.** The results were presented using the median (Me) and
97 interquartile range as 25th (Q₁) and 75th (Q₃) percentiles. The significance of
98 differences between the indicators of independent samples was assessed using the
99 nonparametric Mann-Whitney test (Mann-Whitney U test). The significance of
100 differences in indicators in the dynamics of treatment was determined by the
101 Wilcoxon test (Wilcoxon matched pairs test). Friedman's rank analysis of variance
102 (Friedman ANOVA by Ranks) was also used to assess changes in the studied
103 parameters in the dynamics of postoperative treatment. Statistical analysis was carried
104 out using the Statistica 8.0 software package (StatSoft Inc., USA, 2007).

105

106 **Results**

107 We noticed that the absolute and relative numbers of NKT cell were decreased
108 in patients in the preoperative period with a favorable outcome of DPP if compared
109 to healthy controls, and this was mainly due to cells with CD3⁺CD16⁺CD56⁺ and
110 CD3⁺CD16⁻CD56⁺ phenotypes (Table 1). The absolute number of NKT
111 lymphocytes in patients with a favorable outcome of DPP remained reduced in
112 compared to control values on the 7th day after surgery. An increase in
113 CD3⁺CD16⁻CD56⁺ cells levels if compared with the initial time point was also
114 found, and this content remained until the end of the observed period.

115 Moreover, the consistent increase of CD3⁺CD16⁻CD56⁺ cells frequency was
116 also confirmed by the results of Friedman ANOVA test: $\chi^2=13,08$, $p=0,004$. The
117 absolute number of NKT cells in patients with a favorable outcome of DPP remained
118 on the 14th day of postoperative treatment, but with a decrease in the percentage of

119 CD3⁺CD16⁺CD56⁺ cells vs. control group. Patients with a favorable outcome of
 120 peritonitis showed a normalization of the absolute number of circulating NKT cells
 121 and a reduced percentages of CD3⁺CD16⁺CD56⁻ cells if compared to control values
 122 by the end of the observed period.

123 We found that the level of CD8-expressing NKT cells was altered in patients
 124 with a favorable outcome of DPP (Table 2). Thus, the percentage of peripheral blood
 125 CD3⁺CD8⁺CD16⁺CD56⁺, CD3⁺CD8⁺CD16⁺CD56⁻ and CD3⁺CD8⁺CD16⁻CD56⁺
 126 cells was reduced in this group of patients even in the preoperative period if
 127 compared to healthy controls. The relative number of NKT cells with
 128 CD3⁺CD8⁺CD16⁺CD56⁺ phenotype in patients with a favorable outcome of the
 129 disease was increased vs. control ranges on the 7th day after surgery, and it reached
 130 its maximum by the end of the observed period. The percentage of
 131 CD3⁺CD8⁺CD16⁺CD56⁻ cells in patients of this group increased if compared to
 132 control values on the 7th day after surgery, but it decreased again at 14th day point
 133 and remained at the initial level until the end of the observed period. The frequency
 134 of CD3⁺CD8⁺CD16⁻CD56⁺ NKT cells was reduced on the 7th day post-surgery,
 135 their number was increased vs. control values on the 14th day of treatment, and
 136 reached its maximum by the end of the observed period. The sequence of changes
 137 in the content of NKT cells with this phenotype was also confirmed using the
 138 Friedman ANOVA test ($\chi^2=9.60, p=0.022$).

139 Next, we investigated the expression of cell adhesion molecules and activation
 140 markers by peripheral blood NKT cells (Table 3). We found increased levels of
 141 CD3⁺CD16⁺CD56⁺CD11b⁺ and CD3⁺CD16⁺CD56⁻CD11b⁺ NKT cells in blood
 142 samples from DPP patients with a favorable outcome in compared to controls, while
 143 the frequencies of CD28- and CD57 expressing NKT cells were decreased (Table
 144 3). Moreover, CD3⁺CD16⁺CD56⁺CD11b⁺ cells in patients of this group were
 145 decreased if compared to control values from the 14th day, while the number of
 146 CD3⁺CD16⁺CD56⁻CD11b⁺ cells remained elevated by end of our observed period.
 147 The number of CD3⁺CD16⁻CD56⁺CD11b⁺ NKT cells in the current patients group

148 increased significantly vs. healthy controls only at the end of the observation period,
 149 that was also confirmed by the Friedman ANOVA test ($\chi^2=12.60$, $p=0.006$). The
 150 percentage of NKT cells expressing CD28 and CD57 increased from the beginning
 151 of postoperative treatment and remained at the control levels until the end of the
 152 examination period.

153 The percentage of NKT cells in the blood of patients with DPP with an
 154 unfavorable outcome of the disease was reduced vs. control levels before the
 155 surgery, while their relative number restored after the surgery (Table 4). However,
 156 the absolute number of NKT cells in patients of this group was reduced in
 157 preoperative and postoperative periods if compared to control group. The percentage
 158 of CD3⁺CD16⁺CD56⁺ NKT cells in patients with an unfavorable outcome of DPP
 159 corresponded to the control values in the preoperative period and within 14 days of
 160 subsequent treatment, but it decreased by the end of the observed period. The level
 161 of CD3⁺CD16⁺CD56⁻ cells in patients of this group also corresponded to the control
 162 values in the preoperative period, while it significantly increased by the 7th and 14th
 163 days of observation. Moreover, it returned to initial ranges by the 21st day of
 164 postoperative treatment. At the same time, the percentage of CD3⁺CD16⁻CD56⁺
 165 NKT cells in patients with an unfavorable outcome of DPP was reduced in the
 166 preoperative period, but it reached the control values on the 14th day of
 167 postoperative treatment, and then decreased by the end observed period if compared
 168 to healthy controls.

169 The relative numbers of peripheral blood CD3⁺CD8⁺CD16⁺CD56⁺ and
 170 CD3⁺CD8⁺CD16⁺CD56⁻ cells in patients with an unfavorable outcome of DPP in
 171 the preoperative period corresponded to the control values (Table 5). The
 172 frequencies of CD3⁺CD8⁺CD16⁺CD56⁺ cells were increased by the 7th day after the
 173 surgery, but it significantly decreased by the end of the observed period if compared
 174 to controls. The level of CD3⁺CD8⁺CD16⁺CD56⁻ cells was increased if compared
 175 to control values on the 7th and 14th days of postoperative treatment, but their
 176 number decreased to the initial range by the end of the observed period. The

177 percentage of CD3⁺CD8⁺CD16⁻CD56⁺ cells in patients with an unfavorable
 178 outcome of the disease was reduced in the preoperative period, it increased to control
 179 values on the 7th and 14th days of treatment, but, finally, it was decreased by the
 180 end of the observed period if compared to controls.

181 The percentage of circulating CD3⁺CD16⁺CD56⁺CD11b⁺ cells in patients
 182 with an unfavorable outcome of DPP in the pre- and postoperative period
 183 corresponded to the control range, while the level of CD3⁺CD16⁻CD56⁺CD11b⁺
 184 cells during the entire examination period exceeded the control values (Table 6). The
 185 levels of CD3⁺CD16⁺CD56⁻CD11b⁺ NKT cells in patients of this group in the
 186 preoperative period showed no differences with control values. However, the level
 187 of this cell subset decreased on the 7th day after the surgery, but then increased by
 188 the end of the observed period if compared to healthy controls and initial ranges.

189 The relative numbers of CD28-expressing NKT cells in patients with an
 190 unfavorable outcome of the disease were reduced compared to control values in the
 191 preoperative period and on the 7th day of the postoperative period, but they reached
 192 the control values by the end of the observed period significantly exceeding the
 193 initial level. Similarly, CD57-positive NKT cells in this group of patients were
 194 reduced in the preoperative period and during the first 14 days of postoperative
 195 treatment, but they increased to control values by the end of the observed period.

196 Differences in NKT cells content were found between patients with favorable
 197 and unfavorable outcomes of DPP (Tables 1, 4). Thus, the percentages of
 198 CD3⁺CD16⁺CD56⁺ cells were increased in patients with an unfavorable outcome of
 199 the disease on the 7th day after surgery ($p=0.045$), the level of CD3⁺CD16⁺CD56⁻
 200 cells was increased on the 14th day ($p=0.014$), and the relative content of
 201 CD3⁺CD16⁻CD56⁺ cells were reduced on the 21st day after surgery ($p<0.001$) if
 202 compared to patients with a favorable outcome of DPP. Additionally, the frequencies
 203 of circulating CD3⁺CD8⁺CD16⁺CD56⁺ cells were increased in the case of an
 204 unfavorable outcome of DPP during the preoperative period ($p=0.025$), and the level

205 of CD3⁺CD8⁺CD16⁻CD56⁺ NKT cells was reduced if compared ($p=0.043$) to
 206 patients with a favorable outcome of the disease (Tables 2, 5).

207 At the same time, an increased level of CD3⁺CD8⁺CD16⁺CD56⁺ cells in
 208 patients with an unfavorable outcome persisted on the 7th day after surgery
 209 ($p=0.048$), while a decrease in this NKT cell subset ($p=0.008$) was observed at 21st
 210 day of postoperative treatment if compared to patients with a favorable outcome of
 211 DPP. The percentage of CD3⁺CD8⁺CD16⁻CD56⁺ cells in patients with an
 212 unfavorable outcome also remained lower at the end of the observed period vs.
 213 patients with a favorable outcome of DPP ($p<0.001$). The relative numbers of
 214 CD3⁺CD8⁺CD16⁺CD56⁻ cells in the blood of patients with an unfavorable outcome
 215 of DPP on the 7th and 14th days after surgery were also increased ($p=0.017$ and
 216 $p<0.001$, respectively).

217 Finally, the percentages of CD3⁺CD16⁺CD56⁺CD11b⁺ cells in patients with
 218 an unfavorable outcome of DPP on the 7th and 21st days of postoperative treatment
 219 were reduced vs. patients with a favorable outcome ($p=0.003$ and $p=0.044$,
 220 respectively) (Tables 3, 6). Similarly, the levels of CD3⁺CD16⁺CD56⁻CD11b⁺ NKT
 221 cells were reduced on the 7th and 14th days of postoperative treatment vs. patients
 222 with an unfavorable outcome ($p<0.001$ and $p=0.002$, respectively). An increase in
 223 relative numbers of CD3⁺CD16⁻CD56⁺CD11b⁺ cells in patients with an unfavorable
 224 outcome vs. patients with a favorable outcome were observed only in the
 225 preoperative period ($p=0.002$). In addition, CD28⁺ NKT cells were reduced in
 226 patients with an unfavorable outcome of DPP in the preoperative period and on the
 227 7th day after surgery ($p=0.020$ and $p=0.028$, respectively), and the numbers of
 228 CD57⁺ NKT cells were reduced during the entire observation period ($p=0.043$,
 229 $p=0.007$, $p=0.046$ and $p=0.039$, respectively) relative to the indicators found in
 230 patients with a favorable course of this infectious and inflammatory disease.

231

232 **Discussion**

233 The functional activity of NKT cells is realized through effector
 234 (perforin/granzyme and/or FasL-mediated) mechanisms and regulatory (cytokine
 235 production) providing the relationship between innate and adaptive immunity [6, 12,
 236 40]. The subset composition of NKT cells is determined by CD16 and CD56 receptor
 237 expression. The CD16 is a low affinity immunoglobulin G receptor (FcγRIII) that is
 238 non-covalently bound to the CD3ζ molecule on the NKT cell membrane [17, 18].
 239 CD56 (NCAM, Leu-19, NKH-1) is an immunoglobulin superfamily adhesion
 240 molecule that takes part in intercellular interaction [8, 23]. Mature NKT cells express
 241 both markers. Cells that exhibit CD16⁺CD56⁻ phenotype are defined as cytotoxic
 242 cells, while NKT cells with CD16⁻CD56⁺ phenotype are defined as cytokine-
 243 producing cells [15, 35].

244 In general, the relative and absolute numbers of NKT cells in the peripheral
 245 blood of patients with DPP were reduced in the preoperative period, regardless of
 246 the outcome of the disease. Moreover, if their percentage was restored already on
 247 the 7th day after the surgery then the reduced absolute level of this fraction of
 248 lymphocytes remained in the postoperative period. Only patients with a favorable
 249 outcome of the disease by the end of the observed period (on the 21st day after
 250 surgery) had increased percentages of NKT cells similar to control ranges. A feature
 251 of the dynamics of the number of NKT cells in the blood in patients with a favorable
 252 outcome of DPP was that the reduced level of cells was associated with a low content
 253 of mature and cytokine-producing NKT cells in the preoperative period, while their
 254 number was restored to control values by the end of the observed period and the
 255 number of cytotoxic NKT cells decreased. Patients with an unfavorable outcome of
 256 DPP in the preoperative period had a low level of NKT cells which was determined
 257 by a reduced content of cytokine-producing cells. The low level of cytokine-
 258 producing and mature NKT cells was also observed in patients of this group on the
 259 21st day of postoperative treatment.

260 NKT cells expressing the CD8 marker are part of type II NKT cells (non-
 261 classical, non-invariant) [1, 32]. This cell fraction recognizes a wider range of
 262 antigenic molecules (compared to type I NKT cells), synthesizes cytokines that

263 induce differentiation of Th1- and Th2-lymphocytes but also implement
 264 immunosuppressive functions [1, 14, 36]. In particular, type II NKT cells can
 265 stimulate the functional activity of myeloid suppressor cells, able to kill antigen-
 266 prescribing dendritic cells and to inhibit the functional activity of cytotoxic CD8⁺ T
 267 cells through the induction of TGF- β expression [29, 30].

268 The content of mature, cytotoxic and cytokine-producing fractions of NKT
 269 cells with CD8 expression was reduced in the blood of patients with DPP with a
 270 favorable outcome of the disease in the preoperative period compared with control
 271 values. However, the level of mature and cytokine-producing CD8⁺NKT cells
 272 recovered to the control range by the end of the observed period (on the 21st day
 273 after the surgery). At the same time, a decrease in the content of only cytokine-
 274 producing CD8⁺ NKT cells was found in the examined patients with an unfavorable
 275 outcome of DPP in the preoperative period relative to the control range and values
 276 detected with a favorable outcome; the level of mature CD8⁺ NKT cells even
 277 exceeded that detected in case of a favorable outcome of the disease. However, the
 278 number of all studied fractions of CD8⁺NKT cells was significantly reduced
 279 compared to control values by the 21st day of postoperative treatment.

280 The CD11b receptor is a type I glycoprotein defined as a subunit of the α M
 281 integrin and forms the Mac-1 integrin in complex with the CD18 molecule
 282 (CD11b/CD18) [25, 26]. Expression of this marker on the membrane of NKT cells
 283 increases the level of effector and migratory activity. An increased numbers of
 284 CD11b-expressing mature NKT cells were found in patients with a favorable
 285 outcome of DPP in the preoperative period, their content returned to normal by day
 286 21, while the content of CD11b⁺ cytotoxic NKT cells in the pre- and postoperative
 287 period remained elevated. In addition, the level of cytokine-producing CD11b⁺ NKT
 288 cells in individuals of this group increased towards the end of the observed period.
 289 The patients with an unfavorable outcome of the disease had a lower content of
 290 mature CD11b⁺ NKT cells by the 21st day of the postoperative period compared
 291 with the control values and the level of these cells with a favorable outcome of
 292 peritonitis. In addition, the content of cytotoxic NKT cells significantly increased in

293 patients with an unfavorable outcome only at the end of the observed period, while
294 the level of cytokine-producing CD11b⁺ NKT cells was increased throughout the
295 entire period of the study.

296 Also, the content of NKT cells expressing activation markers CD28 and CD57
297 was studied in patients with DPP in depending on the outcome of the disease. The
298 CD28 antigen (Tp44) belongs to the immunoglobulin superfamily and is involved
299 in the enhancement of T-cell receptor signals, which determines its role in the
300 regulation of adaptive immunity [13, 20]. Blockade of CD28 on the membrane of
301 NKT cells completely suppressed cytokine production [37]. CD57 receptor (Leu-7,
302 HNK-1, NK-1) was defined as an oligosaccharide with sulfated glucuronic acid
303 residues which is expressed on membrane proteins, lipids, and proteoglycans, and
304 its expression level is associated with the accumulation of perforin and granzyme B
305 in the cytolytic killer granules cells [14, 32].

306 The frequencies of CD28⁺ and CD57⁺ NKT cells in the preoperative period
307 was reduced relative to the control values in patients with a favorable outcome of
308 DPP in the preoperative period. However, their number returned to normal
309 immediately after the surgery and remained at the level of the control range until the
310 end of the observed period. At the same time, patients with an unfavorable outcome
311 of peritonitis had low levels of CD28⁺ and CD57⁺ NKT cells in the preoperative
312 period which increased to control values only by the end of the observed period.

313 In general, it can be concluded that the systemic inflammatory response in
314 DPP patients with an unfavorable outcome of the disease in the postoperative period
315 was characterized by a violation of the ratio of the subset composition of NKT cells
316 with a low level of non-classical NKT cells by the end of the observed period (day
317 21 after surgery) and a pronounced change in the cell content expressing adhesion
318 and activation markers.

319

320 **Conclusion**

321 Thus, significant differences in the phenotype of peripheral blood NKT cells
322 were found between patients with different outcome of DPP. The low relative and

323 absolute levels of NKT cells were observed all patients with DPP regardless of the
324 disease outcome in the preoperative period. At the same time, the absolute level of
325 NKT cells returned to normal values only in patients with a favorable outcome of
326 DPP post 21 days after the surgery. The content of mature NKT lymphocytes was
327 normalized in the peripheral blood of patients with a favorable outcome of DPP by
328 the end of the examination period. The number of cytotoxic cells in the blood of
329 these patients significantly decreased by the 21st day of the examination which is
330 apparently determined by their migration to the area of inflammation. At the same
331 time, patients of this group had the level of cytokine-producing cells at the level of
332 the control range during the entire postoperative period.

333 Conversely, the level of mature and cytokine-producing NKT cells was
334 reduced in the blood of patients with an unfavorable outcome of DPP by the 21st
335 day of the postoperative period. A reduced level of non-classical (expressing the
336 CD8 marker) mature and cytokine-producing NKT cells was detected only in
337 patients with a favorable outcome of DPP in the preoperative period which returned
338 to normal by the end of the postoperative period. At the same time, patients with an
339 unfavorable outcome of the disease had a reduced number of NKT cells of these
340 subsets by the 21st day of postoperative treatment. It can be assumed that a high
341 level of systemic inflammatory response in the postoperative period in patients of
342 this category was associated with a lack of regulatory processes in the immune
343 system including a low level of non-classical NKT cells.

344 In addition, it was found that a high level of NKT cells (compared to control
345 values) expressing the CD11b receptor was observed in patients with DPP during
346 the entire period of the study. However, only patients with a favorable outcome of
347 the disease had a high level of mature and cytotoxic CD11b⁺ NKT cells already in
348 the preoperative period, while an increased content of cytotoxic CD11b⁺ NKT cells
349 was found in patients with an unfavorable outcome of peritonitis only by the 21st
350 day after surgery. The content of NKT cells expressing activation markers (CD28,
351 CD57) was reduced in patients in the preoperative period; it returned to normal with
352 a favorable outcome immediately after surgery while patients with an unfavorable

353 outcome had a recovery of these cell fractions towards the end of the postoperative
354 examination. The established features of the phenotype of NKT cells in patients with
355 an unfavorable outcome of DPP characterize disturbances in the ratio of the subset
356 composition and the mechanisms of functioning of this cell fraction. This determines
357 the need to develop immunotherapeutic methods aimed at stimulating the
358 immunoregulatory activity of NKT cells.

ТАБЛИЦЫ

Table 1. Content of blood NKT cells in patients with a favorable DPP outcome in the dynamics of the postoperative period (Me, Q₁ – Q₃)

| Parameters | Control n=68 | Preoperative period n=34 | 7 days after surgery n=34 | 14 days after surgery n=34 | 21 days after surgery n=34 |
|---|---------------------|---|--|--|--|
| CD3 ⁺ CD16 ⁺ 56 ⁺ , % | 3.51 1.98 – 6.90 | 1.90 1.19 – 3.29 p ₁ =0.011 | 3.31 2.19 – 7.12 | 2.84 2.31 – 4.45 | 3.50 3.13 – 5.51 |
| CD3 ⁺ CD16 ⁺ 56 ⁺ , 10 ⁹ /l | 0.07 0.04 – 0.19 | 0.02 0.007 – 0.03 p ₁ =0.007 | 0.03 0.02 – 0.04 p ₁ =0.039 | 0.03 0.01 – 0.05 p ₁ =0.039 | 0.08 0.05 – 0.14 p ₂ =0.043 |
| CD3 ⁺ CD16 ⁺ CD56 ⁺ , % | 0.73 0.43 – 1.25 | 0.37 0.23 – 0.69 p ₁ =0.029 | 0.70 0.37 – 1.00 | 0.39 0.19 – 0.69 p ₁ =0.035 | 0.67 0.43 – 1.01 |
| CD3 ⁺ CD16 ⁺ CD56 ⁻ , % | 0.87 0.56 – 1.06 | 0.85 0.60 – 1.80 | 1.15 0.92 – 1.55 | 0.70 0.51 – 1.25 | 0.39 0.28 – 0.49 p ₁ =0.023 p ₂ =0.021 p ₃ =0.014 |
| CD3 ⁺ CD16 ⁻ CD56 ⁺ , % | 1.93 1.29 – 2.67 | 0.59 0.35 – 1.60 p ₁ =0.004 | 1.50 0.70 – 2.91 p ₂ =0.045 | 1.80 0.50 – 2.41 p ₂ =0.048 | 2.29 1.93 – 2.90 p ₂ <0.001 |

Note: p₁ – statistically significant differences versus controls; p₂ – statistically significant differences versus patients with DPP before surgery; p₃ – statistically significant differences versus 7 days after surgery patients.

Table 2. Subsets of NKT cells with CD8 expression in patients with a favorable DPP outcome in the dynamics of the postoperative period (Me, Q₁ – Q₃)

| Parameters | Control n=68 | Preoperative period n=34 | 7 days after surgery n=34 | 14 days after surgery n=34 | 21 days after surgery n=34 |
|---|---------------------|--|--|---|--|
| CD3 ⁺ CD8 ⁺ CD16 ⁺ CD56 ⁺ , % | 0.55 0.33 – 0.87 | 0.24 0.14 – 0.43 p ₁ =0.018 | 0.60 0.31 – 0.75 | 0.42 0.21 – 0.70 | 0.63 0.38 – 1.02 p ₂ =0.037 |
| CD3 ⁺ CD8 ⁺ CD16 ⁺ CD56 ⁻ , % | 0.18 0.12 – 0.22 | 0.05 0.03 – 0.11 p ₁ <0.001 | 0.13 0.11 – 0.19 | 0.04 0.02 – 0.06 p ₁ <0.001 p ₃ =0.046 | 0.06 0.03 – 0.07 p ₁ <0.001 |
| CD3 ⁺ CD8 ⁺ CD16 ⁻ CD56 ⁺ , % | 1.60 1.14 – 2.22 | 0.60 0.36 – 1.25 p ₁ =0.005 | 0.75 0.34 – 1.49 p ₁ =0.040 | 1.30 0.30 – 1.72 | 1.60 1.35 – 2.10 p ₂ =0.043 |

Note: p₁ – statistically significant differences versus controls; p₂ – statistically significant differences versus patients with DPP before surgery; p₃ – statistically significant differences versus 7 days after surgery patients.

Table 3. Content of NKT cells expressing activation and adhesion markers in patients with a favorable DPP outcome in the dynamics of the postoperative period (Me, Q₁ – Q₃)

| Parameters | Control n=68 | Preoperative period n=34 | 7 days after surgery n=34 | 14 days after surgery n=34 | 21 days after surgery n=34 |
|---|------------------------|---|---|---|---|
| CD3 ⁺ CD16 ⁺ CD56 ⁺ CD11b ⁺ , % | 0.012 0.003 – 0.041 | 0.043 0.017 – 0.074 p ₁ =0.035 | 0.059 0.028 – 0.114 p ₁ =0.030 | 0.031 0.014 – 0.049 p ₃ =0.041 | 0.030 0.005 – 0.110 |
| CD3 ⁺ CD16 ⁺ CD56 ⁻ CD11b ⁺ , % | 0.022 0.011 – 0.029 | 0.043 0.022 – 0.059 p ₁ =0.047 | 0.059 0.040 – 0.310 p ₁ =0.023 | 0.039 0.021 – 0.113 | 0.061 0.022 – 0.153 p ₁ =0.045 |
| CD3 ⁺ CD16 ⁻ CD56 ⁺ CD11b ⁺ , % | 0.132 0.089 – 0.789 | 0.369 0.249 – 0.609 | 0.509 0.439 – 0.989 | 0.389 0.219 – 0.690 | 0.680 0.556 – 1.170 p ₁ =0.041 |
| CD3 ⁺ CD16/56 ⁺ CD28 ⁺ , % | 1.50 0.83 – 3.20 | 0.89 0.49 – 1.59 p ₁ =0.044 | 1.46 0.58 – 3.21 p ₂ =0.047 | 0.90 0.60 – 2.70 | 1.00 0.54 – 4.43 |
| CD3 ⁺ CD16/56 ⁺ CD57 ⁺ , % | 1.32 0.22 – 2.32 | 0.96 0.66 – 1.69 p ₁ =0.045 | 1.20 0.70 – 2.18 | 1.34 0.71 – 1.72 | 1.40 1.13 – 1.83 |

Note: p₁ – statistically significant differences versus controls; p₂ – statistically significant differences versus patients with DPP before surgery; p₃ – statistically significant differences versus 7 days after surgery patients.

Table 4. Content of blood NKT cells in patients with an unfavorable DPP outcome in the dynamics of the postoperative period (Me, Q₁ – Q₃)

| Parameters | Control n=68 | Preoperative period n=18 | 7 days after surgery n=18 | 14 days after surgery n=18 | 21 days after surgery n=18 |
|--|---------------------|--|---|--|---|
| CD3 ⁺ CD16/56 ⁺ , % | 3.51 1.98 – 6.90 | 2.09 1.36 – 2.69 p ₁ =0.025 | 3.47 1.34 – 5.53 | 3.89 0.67 – 5.70 | 2.30 1.43 – 4.88 |
| CD3 ⁺ CD16/56 ⁺ , 10 ⁹ /l | 0.07 0.04 – 0.19 | 0.02 0.01 – 0.03 p ₁ <0.001 | 0.02 0.01 – 0.04 p ₁ =0.004 | 0.02 0.01 – 0.05 p ₁ =0.021 | 0.03 0.01 – 0.06 p ₁ =0.045 |
| CD3 ⁺ CD16 ⁺ CD56 ⁺ , % | 0.73 0.43 – 1.25 | 0.60 0.15 – 1.30 | 0.85 0.76 – 1.79 | 0.48 0.41 – 0.95 | 0.39 0.25 – 0.53 p ₁ =0.043 p ₃ =0.038 |
| CD3 ⁺ CD16 ⁺ CD56 ⁻ , % | 0.87 0.56 – 1.06 | 0.75 0.37 – 1.40 | 1.50 1.28 – 3.45 p ₁ <0.001 p ₂ =0.029 | 1.37 1.00 – 2.15 p ₁ =0.034 | 0.65 0.34 – 1.10 |
| CD3 ⁺ CD16 ⁻ CD56 ⁺ , % | 1.93 1.29 – 2.67 | 0.69 0.25 – 1.42 p ₁ =0.010 | 1.19 0.93 – 1.32 p ₁ =0.041 | 2.25 1.30 – 3.65 p ₂ =0.044 | 1.14 0.82 – 1.37 p ₁ =0.040 p ₄ =0.047 |

Note: p_1 – statistically significant differences versus controls; p_2 – statistically significant differences versus patients with DPP before surgery; p_3 – statistically significant differences versus 7 days after surgery patients, p_4 – statistically significant differences versus 14 days after surgery patients.

Table 5. Subsets of NKT cells with CD8 expression in patients with an unfavorable DPP outcome in the dynamics of the postoperative period (Me, Q_1 – Q_3)

| Parameters | Control n=68 | Preoperative period n=18 | 7 days after surgery n=18 | 14 days after surgery n=18 | 21 days after surgery n=18 |
|---|---------------------|------------------------------------|------------------------------------|------------------------------------|---|
| CD3 ⁺ CD8 ⁺ CD16 ⁺ CD56 ⁺ , % | 0.55 0.33 – 0.87 | 0.56 0.14 – 1.30 | 0.84 0.75 – 1.79 $p_1=0.043$ | 0.39 0.20 – 0.89 $p_3=0.040$ | 0.29 0.10 – 0.39 $p_1=0.040$ $p_3=0.008$ |
| CD3 ⁺ CD8 ⁺ CD16 ⁺ CD56 ⁻ , % | 0.18 0.12 – 0.22 | 0.10 0.06 – 0.90 | 0.60 0.14 – 1.28 $p_1=0.044$ | 0.70 0.32 – 1.08 $p_1<0.001$ | 0.13 0.05 – 0.49 $p_4=0.027$ |
| CD3 ⁺ CD8 ⁺ CD16 ⁻ CD56 ⁺ , % | 1.60 1.14 – 2.22 | 0.19 0.07 – 0.87 $p_1<0.001$ | 0.79 0.30 – 2.09 | 0.83 0.49 – 1.85 $p_2=0.047$ | 0.64 0.19 – 0.71 $p_1<0.001$ |

Note: p_1 – statistically significant differences versus controls; p_2 – statistically significant differences versus patients with DPP before surgery; p_3 – statistically significant differences versus 7 days after surgery patients, p_4 – statistically significant differences versus 14 days after surgery patients.

Table 6. Content of NKT cells expressing activation and adhesion markers in patients with an unfavorable DPP outcome in the dynamics of the postoperative period (Me, $Q_1 - Q_3$)

| Parameters | Control n=68 | Preoperative period n=18 | 7 days after surgery n=18 | 14 days after surgery n=18 | 21 days after surgery n=18 |
|---|------------------------|---|---|---|--|
| CD3 ⁺ CD16 ⁺ CD56 ⁺ CD11b ⁺ , % | 0.012 0.003 – 0.041 | 0.033 0.006 – 0.174 | 0.017 0.006 – 0.029 | 0.045 0.019 – 0.095 | 0.006 0.004 – 0.029 |
| CD3 ⁺ CD16 ⁺ CD56 ⁻ CD11b ⁺ , % | 0.022 0.011 – 0.029 | 0.017 0.006 – 0.104 | 0.007 0.003 – 0.008 $p_1 < 0.001$ | 0.010 0.004 – 0.025 | 0.074 0.069 – 0.084 $p_{1,2,3} < 0.001$ $p_4 = 0.014$ |
| CD3 ⁺ CD16 ⁻ CD56 ⁺ CD11b ⁺ , % | 0.132 0.089 – 0.789 | 1.079 0.623 – 1.205 $p_1 = 0.024$ | 0.812 0.225 – 2.550 $p_1 = 0.037$ | 0.640 0.210 – 1.374 $p_1 = 0.046$ | 0.993 0.337 – 2.260 $p_1 = 0.018$ |
| CD3 ⁺ CD16/56 ⁺ CD28 ⁺ , % | 1.50 0.83 – 3.20 | 0.34 0.16 – 1.14 $p_1 = 0.006$ | 0.56 0.41 – 1.29 $p_1 = 0.016$ | 1.40 0.30 – 2.71 | 1.90 1.00 – 2.35 $p_2 = 0.045$ |
| CD3 ⁺ CD16/56 ⁺ CD57 ⁺ , % | 1.32 0.22 – 2.32 | 0.59 0.04 – 0.85 $p_1 = 0.011$ | 0.20 0.03 – 1.00 $p_1 = 0.031$ | 0.49 0.04 – 1.09 $p_1 = 0.038$ | 1.00 0.20 – 1.11 |

Note: p_1 – statistically significant differences versus controls; p_2 – statistically significant differences versus patients with DPP before surgery; p_3 – statistically significant differences versus 7 days after surgery patients; p_4 – statistically significant differences versus 14 days after surgery patients.

ТИТУЛЬНЫЙ ЛИСТ_МЕТАДААННЫЕ

Блок 1. Информация об авторе, ответственном за переписку

Кудрявцев Игорь Владимирович (кандидат биологических наук, заведующий лабораторией), кафедра иммунологии ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения РФ, Санкт-Петербург, Россия; отдел иммунологии ФГБНУ «Институт экспериментальной медицины», Санкт-Петербург, Россия.

197376, Санкт-Петербург, ул. академика Павлова, 12. ФГБНУ «Институт экспериментальной медицины», +7-812-234-29-29, igorek1981@yandex.ru

Kudryavtsev Igor Vladimirovich, PhD (Biology), Senior Researcher, Assistant Professor, Department of Immunology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia; Laboratory Head, Federal State Budgetary Scientific Institution 'Institute of Experimental Medicine' (FSBSI 'IEM'), St. Petersburg, Russia;

197376, St. Petersburg, Acad. Pavlov Street 12, Scientific Research Institute of Experimental Medicine, +7 812-234-29-29, igorek1981@yandex.ru

Блок 2. Информация об авторах

Савченко Андрей Анатольевич, д.м.н., профессор, руководитель лаборатории клеточно-молекулярной физиологии и патологии ФГБНУ Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук», обособленное подразделение «НИИ медицинских проблем Севера», профессор кафедры медицинской биологии ФГАОУ ВО «Сибирский федеральный университет».

Savchenko Andrei Anatyevich, Doctor of Medicine, Professor, Head of the Cellular-molecular Physiology and Pathology Laboratory, Federal Research Center 'Krasnoyarsk Science Center', Siberian Branch of the Russian Academy of Sciences,

Scientific Research Institute of Medical Problems of the North; Professor, Medical Biology Department, Siberian Federal University.

Адрес: 660022, Россия, Красноярский край, г. Красноярск, ул. Партизана Железняка, 3Г. Институт медицинских проблем Севера.

660022, Russia, Krasnoyarsk region, Krasnoyarsk, Partizana Zheleznjaka Street, 3G. Scientific Research Institute of Medical Problems of the North.

Борисов Александр Геннадьевич, к.м.н., ведущий научный сотрудник лаборатории клеточно-молекулярной физиологии и патологии ФГБНУ Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук», обособленное подразделение «НИИ медицинских проблем Севера.

Borisov Alexandr Gennadyevich, PhD, Leading Researcher, Cellular-molecular Physiology and Pathology Laboratory, Federal Research Center 'Krasnoyarsk Science Center', Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North.

Адрес: 660022, Россия, Красноярский край, г. Красноярск, ул. Партизана Железняка, 3Г. Институт медицинских проблем Севера.

660022, Russia, Krasnoyarsk region, Krasnoyarsk, Partizana Zheleznjaka Street, 3G. Scientific Research Institute of Medical Problems of the North.

Беленюк Василий Дмитриевич, младший научный сотрудник лаборатории клеточно-молекулярной физиологии и патологии ФГБНУ Федеральный исследовательский центр «Красноярский научный центр Сибирского отделения Российской академии наук», обособленное подразделение «НИИ медицинских проблем Севера».

Belenjuk Vasilij Dmitrievich, Junior Researcher, Cellular-molecular Physiology and Pathology Laboratory, Federal Research Center 'Krasnoyarsk Science Center, Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North.

Адрес: 660022, Россия, Красноярский край, г. Красноярск, ул. Партизана Железняка, 3Г. Институт медицинских проблем Севера.

Блок 3. Метаданные статьи

ОСОБЕННОСТИ ФЕНОТИПА НКТ-КЛЕТОК В ЗАВИСИМОСТИ ОТ
ИСХОДА РАСПРОСТРАНЕННОГО ГНОЙНОГО ПЕРИТОНИТА
DISSEMINATED PURULENT PERITONITIS OUTCOME AFFECTS NKT
CELL PHENOTYPE

Ключевые слова: перитонит; НКТ-клетки; фенотип; исход заболевания;
послеоперационный период, CD3⁻CD56⁺

Keywords: peritonitis; NKT cells; phenotype; disease outcome; postoperative
period, CD3⁻CD56⁺

Сокращенное название статьи для верхнего колонтитула:

НКТ-клетки при перитоните

NKT cells in peritonitis

Количество страниц текста – 12, количество таблиц – 6.

Оригинальная статья

Дата отправления работы: 22.07.2022

СПИСОК ЛИТЕРАТУРЫ

| Порядковый номер ссылки | Авторы, название публикации и источника, где она опубликована, выходные данные | ФИО, название публикации и источника на английском | Полный интернет-адрес (URL) цитируемой статьи или ее doi. |
|-------------------------|--|---|---|
| 1 | Акинфиева О.В., Бубнова Л.Н., Бессмельцев С.С. NKT-клетки: характерные свойства и функциональная значимость для регуляции иммунного ответа // Онкогематология, 2010, № 4, С. 39-47. | Akinfieva O.V., Bubnova L.N., Bessmeltsev S.S. NKT cells: characteristic properties and functional significance for the regulation of the immune response. <i>Oncohematology</i> , 2010, no. 4, pp. 39-47. | https://cyberleninka.ru/article/n/nkt-kletki-harakternye-svoystva-i-funktsionalnaya-znachimost-dlya-regulyatsii-immunnogo-otveta |
| 2 | Беленюк В.Д., Савченко А.А., Борисов А.Г., Кудрявцев И.В. Особенности фенотипа В-лимфоцитов крови в зависимости от исхода распространенного гнойного перитонита // Инфекция и иммунитет, 2021, Т. 11, № 3, С. 454-462. | Belenjuk V.D., Savchenko A.A., Borisov A.G., Kudryavtsev I.V. Features of peripheral blood B-cell subset phenotype are associated with clinical outcome of widespread purulent peritonitis. <i>Russian Journal of Infection and Immunity</i> , 2021, Vol. 11, no. 3, pp. 454-462. | doi: 10.15789/2220-7619-CBC-1397 |
| 3 | Борисов Р.Н., Здзитовецкий Д.Э., Каспаров Э.В., Савченко А.А., | Borisov R.N., Zdzitovetskii D.E., Kasparov E.V., Savchenko A.A., | doi 10.20333/2500136-2019-5-80-87 |

| | | | |
|---|--|---|--|
| | Борисов С.А., Бердников Д.С., Говоруха Е.С., Болдырев П.Н. Типы реакции иммунной системы и их характеристика у больных распространенным гнойным перитонитом // Сибирское медицинское обозрение, 2019, № 5, С. 80-87. | Borisov S.A., Berdnikov D.S., Govorukha E.S., Boldyrev P.N. Types of immune system reactions and their characteristic in patients with generalized purulent peritonitis. <i>Siberian Medical Review</i> , 2019, no. 5, pp. 80-87 | |
| 4 | Кудрявцев И.В., Субботовская А.И. Опыт измерения параметров иммунного статуса с использованием шестицветного цитофлуориметрического анализа // Медицинская иммунология, 2015, Т. 17, № 1, С. 19-26. | Kudryavtsev I.V., Subbotovskaya A.I. Experience in measuring the parameters of the immune status using six-color cytofluorimetric analysis. <i>Meditinskaya immunologiya = Medical Immunology (Russia)</i> , 2015, Vol. 17, no. 1, pp. 19-26. | doi: 10.15789/1563-0625-2015-1-19-26] |
| 5 | Савченко А.А., Борисов А.Г., Черданцев Д.В., Первова О.В., Кудрявцев И.В., Гвоздев И.И., Мошев А.В. Особенности фенотипа и активности NAD(P)-зависимых дегидрогеназ нейтрофилов у больных распространенным гнойным перитонитом в прогнозе развития сепсиса // Инфекция и | Savchenko A.A., Borisov A.G., Cherdancev D.V., Pervova O.V., Kudryavtsev I.V., Gvozdev I.I., Moshev A.V. Features of the phenotype and NAD(P)-dependent dehydrogenases activity in neutrophil by patients with widespread purulent peritonitis in prognosis for sepsis development. | doi: 10.15789/2220-7619-2018-3-369-376 |

| | | | |
|---|---|---|---|
| | иммунитета, 2018, Т. 8, № 3, С. 369-376. | <i>Russian Journal of Infection and Immunity, 2018, Vol. 8, no. 3, pp. 369-376.</i> | |
| 6 | Табакон Д.В., Заботина Т.Н., Борунова А.А., Панчук И.О., Короткова О.В., Кадагидзе З.Г. Гетерогенность популяций НК и NKT-лимфоцитов у здоровых доноров // Медицинская иммунология, 2017, Т. 19 № 4, С. 401-408. | Tabakov D.V., Zabolina T.N., Borunova A.A., Panchuk I.O., Korotkova O.V., Kadagidze Z.G. Heterogeneity of NK and NKT lymphocyte populations in healthy donors. <i>Meditinskaya immunologiya = Medical Immunology (Russia), 2017, Vol. 19, no. 4, pp. 401-408.</i> | https://doi.org/10.15789/1563-0625-2017-4-401-408 |
| 7 | Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян Арег А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлуориметрованализаторов» (проект) // Медицинская иммунология, 2012, Т. 14, № 3, С. 255-268. | Khaydukov S.V., Baydun L.A., Zurochka A.V., Totolian Areg A. Standardized technology «Research of lymphocytes subpopulation composition in peripheral blood using flow cytometry analyzers» (Draft). <i>Meditinskaya immunologiya = Medical Immunology (Russia), 2012, Vol. 14, no. 3, pp. 255-268.</i> | doi: 10.15789/1563-0625-2012-3-255-268 |

| | | | |
|----|---|--|---|
| 8 | Almeida J.S., Couceiro P., López-Sejas N., Alves V., Růžicková L., Tarazona R., Solana R., Freitas-Tavares P., Santos-Rosa M., Rodrigues-Santos P. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. <i>Front. Immunol.</i> , 2019, Vol. 10, pp. 2493. | | doi: 10.3389/fimmu.2019.02493 |
| 9 | Bae E.A., Seo H., Kim I.K., Jeon I., Kang C.Y. Roles of NKT cells in cancer immunotherapy. <i>Arch. Pharm. Res.</i> , 2019, Vol. 42, no. 7, pp. 543-548. | | doi: 10.1007/s12272-019-01139-8 |
| 10 | Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. <i>Annu. Rev. Immunol.</i> , 2007, Vol. 25, pp. 297-336. | | doi: 10.1146/annurev.immunol.25.022106.141711 |
| 11 | Brailey P.M., Lebrusant-Fernandez M., Barral P. NKT cells and the regulation of intestinal immunity: a two-way street. <i>FEBS J.</i> , 2020, Vol. 287, no. 9, pp. 1686-1699. | | doi: 10.1111/febs.15238 |
| 12 | Cairo C., Webb T.J. Effective Barriers: The Role of NKT Cells and Innate Lymphoid Cells in the Gut. <i>J.</i> | | doi: 10.4049/jimmunol.2100799 |

| | | | |
|----|--|--|---------------------------------|
| | Immunol., 2022, Vol. 208, no. 2, pp. 235-246. | | |
| 13 | Ceeraz S., Thompson C.R., Beatson R., Choy E.H. Harnessing CD8+CD28-Regulatory T Cells as a Tool to Treat Autoimmune Disease. <i>Cells</i> , 2021, Vol. 10, no. 11, pp. 2973. | | doi: 10.3390/cells10112973 |
| 14 | Chen Y., Tian Z. Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer. <i>Cell. Mol. Immunol.</i> , 2021, Vol. 18, no. 1, pp. 57-72. | | doi: 10.1038/s41423-020-00561-z |
| 15 | Cichoż-Lach H., Grywalska E., Michalak A., Kowalik A., Mielnik M., Roliński J. Deviations in Peripheral Blood Cell Populations are Associated with the Stage of Primary Biliary Cholangitis and Presence of Itching. <i>Arch. Immunol. Ther. Exp. (Warsz)</i> , 2018, Vol. 66, no. 6, pp. 443-452. | | doi: 10.1007/s00005-018-0515-9 |
| 16 | de Andrés C., Fernández-Paredes L., Tejera-Alhambra M., Alonso B., Ramos-Medina R., Sánchez-Ramón S. Activation of Blood | | doi: 10.3389/fimmu.2017.00196 |

| | | | |
|----|---|--|--|
| | CD3+CD56+CD8+ T Cells during Pregnancy and Multiple Sclerosis. <i>Front. Immunol.</i> , 2017, Vol. 8, pp. 196. | | |
| 17 | Farrington L.A., Callaway P.C., Vance H.M., Baskevitch K., Lutz E., Warriar L., McIntyre T.I., Budker R., Jagannathan P., Nankya F., Musinguzi K., Nalubega M., Sikyomu E., Naluwu K., Arinaitwe E., Dorsey G., Kanya M.R., Feeney M.E. Opsonized antigen activates V δ 2+ T cells via CD16/FC γ RIIIa in individuals with chronic malaria exposure. <i>PLoS Pathog.</i> , 2020, Vol. 16, no. 10, e1008997. | | doi: 10.1371/journal.ppat. 1008997 |
| 18 | Ferrari L., Martelli P., Saleri R., De Angelis E., Ferrarini G., Cavalli V., Passeri B., Bazzoli G., Ogno G., Magliani W., Borghetti P. An engineered anti-idiotypic antibody-derived killer peptide (KP) early activates swine inflammatory monocytes, CD3+CD16+ natural killer T cells and CD4+CD8 α + double positive CD8 β + cytotoxic T | | doi: 10.1016/j.cimid. 2020.101523 |

| | | | |
|----|--|--|--------------------------------|
| | lymphocytes associated with TNF- α and IFN- γ secretion. <i>Comp. Immunol. Microbiol. Infect. Dis.</i> , 2020, Vol. 72, pp. 101523. | | |
| 19 | Gao Y.L., Yao Y., Zhang X., Chen F., Meng X.L., Chen X.S., Wang C.L., Liu Y.C., Tian X., Shou S.T., Chai Y.F. Regulatory T Cells: Angels or Demons in the Pathophysiology of Sepsis? <i>Front. Immunol.</i> , 2022, Vol. 13, pp. 829210. | | doi: 10.3389/fimmu.2022.829210 |
| 20 | González-Osuna L., Sierra-Cristancho A., Cafferata E.A., Melgar-Rodríguez S., Rojas C., Carvajal P., Cortez C., Vernal R. Senescent CD4+CD28- T Lymphocytes as a Potential Driver of Th17/Treg Imbalance and Alveolar Bone Resorption during Periodontitis. <i>Int. J. Mol. Sci.</i> , 2022, Vol. 23, no. 5, pp. 2543. | | doi: 10.3390/ijms23052543 |
| 21 | Goswami M., Sharma D., Khan N.M., Checker R., Sandur S.K., Jawali N. Antioxidant supplementation enhances bacterial peritonitis in mice by | | doi: 10.1099/jmm.0.067173-0 |

| | | | |
|----|--|--|---|
| | inhibiting phagocytosis. <i>J. Med. Microbiol.</i> , 2014, Vol. 63, Pt. 3, pp. 355-366. | | |
| 22 | Hu J., Yi B., Zhang H. Influence of climatic factors on single-center peritoneal dialysis-associated peritonitis. <i>Zhong Nan Da Xue Xue Bao Yi Xue Ban</i> , 2022, Vol. 47, no. 5, pp. 639-649. | | doi: 10.11817/j.issn.1672-7347.2022.210506 |
| 23 | Huang H., Liu Y., Ouyang X., Wang H., Zhang Y. Identification of a peptide targeting CD56. <i>Immunobiology</i> , 2020, Vol. 225, no. 4, pp. 151982. | | doi: 10.1016/j.imbio.2020.151982 |
| 24 | Ibidapo-Obe O., Stengel S., Köse-Vogel N., Quickert S., Reuken P.A., Busch M., Bauer M., Stallmach A., Bruns T. Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. <i>Cell. Mol. Gastroenterol. Hepatol.</i> , 2020, Vol. 9, no. 4, pp. 661-677. | | doi: 10.1016/j.jcmgh.2020.01.003 |

| | | | |
|----|--|--|-------------------------------------|
| 25 | Kabanov D.S., Grachev S.V., Prokhorenko I.R. Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes. <i>Oxid. Med. Cell. Longev.</i> , 2020, Vol. 2020, pp. 5708692. | | doi: 10.1155/2020/5708692 |
| 26 | Khan S.Q., Khan I., Gupta V. CD11b Activity Modulates Pathogenesis of Lupus Nephritis. <i>Front. Med. (Lausanne)</i> , 2018, Vol. 5, pp. 52. | | doi: 10.3389/fmed.2018.00052 |
| 27 | Kumar V.V., Verma A., Thakur D.S., Somashekar U., Kothari R., Sharma D. Prophylactic mesh placement in emergency midline laparotomy for intestinal perforation peritonitis: An appeal for caution. <i>Trop. Doct.</i> , 2022, Vol. 23, e494755221110831. | | doi: 10.1177/00494755221110831 |
| 28 | Lotte R., Courdurié A., Gaudart A., Emery A., Chevalier A., Tran A., Payen M., Ruimy R. Spontaneous Bacterial Peritonitis: The Incremental Value of a Fast and Direct Bacterial Identification from Ascitic Fluids Inoculated in Blood | | doi: 10.3390/microorganisms10061188 |

| | | | |
|----|---|--|---------------------------------|
| | Culture Bottles by MALDI-TOF MS for a Better Management of Patients. <i>Microorganisms</i> , 2022, Vol. 10, no. 6, pp. 1188. | | |
| 29 | Lu Y., Li Y., Zhou W., Ding B., Yu Q. Regulatory T cells regulate the distribution of natural killer T cells through CD39 signal transduction in asthma. <i>Hum. Cell.</i> , 2019, Vol. 32, no. 2, pp. 141-149. | | doi: 10.1007/s13577-018-00226-0 |
| 30 | Ngiow S.F., Young A. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies. <i>Front. Immunol.</i> , 2020, Vol. 11, pp. 1633. | | doi: 10.3389/fimmu.2020.01633 |
| 31 | Nilsson J., Hörnberg M., Schmidt-Christensen A., Linde K., Nilsson M., Carlus M., Erttmann S.F., Mayans S., Holmberg D. NKT cells promote both type 1 and type 2 inflammatory responses in a mouse model of liver fibrosis. <i>Sci. Rep.</i> , 2020, Vol. 10, no. 1, pp. 21778. | | doi: 10.1038/s41598-020-78688-2 |

| | | | |
|----|--|--|---------------------------------|
| 32 | Noma H., Eshima K., Satoh M., Iwabuchi K. Differential dependence on nuclear factor- κ B-inducing kinase among natural killer T-cell subsets in their development. <i>Immunology</i> , 2015, Vol. 146, no. 1, pp. 89-99. | | doi: 10.1111/imm.12484 |
| 33 | Pinson J., Tuech J.J., Ouaissi M., Mathonnet M., Mauvais F., Houivet E., Lacroix E., Rondeaux J., Sabbagh C., Bridoux V. Role of protective stoma after primary anastomosis for generalized peritonitis due to perforated diverticulitis-DIVERTI 2 (a prospective multicenter randomized trial): rationale and design (nct04604730). <i>BMC Surg.</i> , 2022, Vol. 22, no. 1, pp. 191. | | doi: 10.1186/s12893-022-01589-w |
| 34 | Rajabaleyan P., Michelsen J., Tange Holst U., Möller S., Toft P., Luxhøi J., Buyukuslu M., Bohm A.M., Borly L., Sandblom G., Kobborg M., Aagaard Poulsen K., Schou Løve U., Ovesen S., Grant Sølling C., Mørch Søndergaard B., Lund Lomholt M., Ritz Møller D., Qvist N., Bremholm Ellebæk M.; VACOR study group. Vacuum-assisted | | doi: 10.1186/s13017-022-00427-x |

| | | | |
|----|---|--|---------------------------------|
| | closure versus on-demand relaparotomy in patients with secondary peritonitis- the VACOR trial: protocol for a randomised controlled trial. <i>World J. Emerg. Surg.</i> , 2022, Vol. 17, no. 1, pp. 25. | | |
| 35 | Senpuku H., Miyazaki H., Yoshihara A., Yoneda S., Narisawa N., Kawarai T., Nakagawa N., Miyachi M., Tada A., Yoshida G., Shimada M., Ohashi M., Nishimuta M., Kimura Y., Yoshitake Y. CD56(dim)CD16(high) and CD56(bright)CD16(-) cell percentages associated with maximum knee extensor strength and incidence of death in elderly. <i>Springerplus</i> , 2016, Vol. 5, pp. 244. | | doi: 10.1186/s40064-016-1884-3 |
| 36 | Shen H., Gu C., Liang T., Liu H., Guo F., Liu X. Unveiling the heterogeneity of NKT cells in the liver through single cell RNA sequencing. <i>Sci. Rep.</i> , 2020, Vol. 10, no. 1, pp. 19453. | | doi: 10.1038/s41598-020-76659-1 |
| 37 | Shissler S.C., Singh N.J., Webb T.J. Thymic resident NKT cell subsets show | | doi: 10.1038/s41598-020-65129-3 |

| | | | |
|----|---|--|-----------------------------------|
| | differential requirements for CD28 co-stimulation during antigenic activation. <i>Sci. Rep.</i> , 2020, Vol. 10, no. 1, pp. 8218. | | |
| 38 | Stengel S., Quickert S., Lutz P., Ibdapo-Obe O., Steube A., Köse-Vogel N., Yarbakht M., Reuken P.A., Busch M., Brandt A., Bergheim I., Deshmukh S.D., Stallmach A., Bruns T. Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2020, Vol. 158, no. 6, pp. 1745-1761. | | doi: 10.1053/j.gastro.2020.01.029 |
| 39 | Terabe M., Berzofsky J.A. Tissue-Specific Roles of NKT Cells in Tumor Immunity. <i>Front. Immunol.</i> , 2018, Vol. 9, pp. 1838. | | doi: 10.3389/fimmu.2018.01838 |
| 40 | Vogt S., Mattner J. NKT Cells Contribute to the Control of Microbial Infections. <i>Front. Cell. Infect. Microbiol.</i> , 2021, Vol. 11, pp. 718350. | | doi: 10.3389/fcimb.2021.718350 |

| | | | |
|----|--|--|-----------------------------------|
| 41 | Yang L., Liu S., Zhang Q., Jia S., Qiu C., Jin Z. Overexpression of ascitic interleukin-35 induces CD8+ T cell exhaustion in liver cirrhotic patients with spontaneous bacterial peritonitis. <i>Int. Immunopharmacol.</i> , 2022, Vol. 108, pp. 108729. | | doi: 10.1016/j.intimp.2022.108729 |
|----|--|--|-----------------------------------|